Momenta Pharmaceuticals, Inc. (MNTA) Position Lifted by BlackRock Inc.

BlackRock Inc. lifted its stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 7.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,400,485 shares of the biotechnology company’s stock after buying an additional 626,415 shares during the period. BlackRock Inc. owned approximately 12.81% of Momenta Pharmaceuticals worth $158,868,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Tortoise Investment Management LLC purchased a new position in shares of Momenta Pharmaceuticals in the 2nd quarter valued at $114,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Momenta Pharmaceuticals in the 1st quarter valued at $158,000. BNP Paribas Arbitrage SA grew its position in shares of Momenta Pharmaceuticals by 13.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 13,393 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 1,570 shares during the last quarter. Envestnet Asset Management Inc. grew its position in shares of Momenta Pharmaceuticals by 3.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 14,275 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 411 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan grew its position in shares of Momenta Pharmaceuticals by 2.2% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 14,600 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 310 shares during the last quarter. 93.88% of the stock is currently owned by hedge funds and other institutional investors.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 35,667 shares of the business’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $19.03, for a total transaction of $678,743.01. Following the completion of the sale, the president now owns 286,121 shares in the company, valued at $5,444,882.63. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, President Craig A. Wheeler sold 4,116 shares of the business’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $15.07, for a total transaction of $62,028.12. Following the sale, the president now owns 269,231 shares of the company’s stock, valued at approximately $4,057,311.17. The disclosure for this sale can be found here. In the last quarter, insiders have sold 79,663 shares of company stock valued at $1,414,498. 4.40% of the stock is owned by insiders.

A number of research analysts recently commented on MNTA shares. Goldman Sachs Group, Inc. (The) started coverage on shares of Momenta Pharmaceuticals in a research report on Thursday, September 28th. They issued a “neutral” rating and a $18.00 target price on the stock. Stifel Nicolaus reaffirmed a “buy” rating and issued a $26.00 target price on shares of Momenta Pharmaceuticals in a research report on Thursday, August 3rd. Zacks Investment Research downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Barclays PLC reaffirmed an “equal weight” rating and issued a $16.00 target price (down from $17.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 4th. Finally, BidaskClub downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 6th. Three equities research analysts have rated the stock with a sell rating and nine have given a hold rating to the company’s stock. Momenta Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $15.00.

Shares of Momenta Pharmaceuticals, Inc. (MNTA) opened at 12.90 on Friday. The company’s 50-day moving average is $16.36 and its 200-day moving average is $15.77. Momenta Pharmaceuticals, Inc. has a 52 week low of $10.75 and a 52 week high of $19.90. The firm’s market cap is $955.32 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The firm had revenue of $23.57 million during the quarter, compared to analyst estimates of $24.64 million. During the same quarter in the previous year, the firm earned ($0.31) earnings per share. The firm’s revenue for the quarter was down 10.8% compared to the same quarter last year. Analysts forecast that Momenta Pharmaceuticals, Inc. will post ($1.50) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Position Lifted by BlackRock Inc.” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/2956804/momenta-pharmaceuticals-inc-mnta-position-lifted-by-blackrock-inc.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.